Kirakli Cenk, Cerci Tutku, Ucar Zeynep Zeren, Erer Onur Fevzi, Bodur Hakan Alp, Bilaceroglu Semra, Ozkan Serir Aktogu
Intensive Care Unit, Izmir Training and Research Hospital for Thoracic Medicine and Surgery, Izmir, Turkey.
Respiration. 2008;75(4):402-10. doi: 10.1159/000105540. Epub 2007 Jul 11.
Noninvasive ventilation (NIV) is being increasingly used in hypercapnic chronic obstructive pulmonary disease (COPD) patients but the most appropriate ventilation mode is still not known.
The aim of this study was to investigate if assisted pressure-controlled ventilation (APCV) can be a better alternative to pressure-support ventilation (PSV) for NIV in COPD patients with acute hypercapnic respiratory failure (AHRF).
In this prospective randomized study, we evaluated the early effects of noninvasive APCV and PSV in 34 consecutive COPD patients with AHRF. Patients were randomized into 1 of the 2 modes, and respiratory and hemodynamic values were compared before and after 1 h of NIV.
Baseline values did not differ between the 2 groups. There were significant improvements in partial arterial carbon dioxide pressure and pH levels in the APCV group when compared with baseline (p < 0.05). Cardiac output and cardiac index decreased in both groups (p < 0.05) but more significantly in the PSV group (p < 0.0001). The decreases in stroke volume index and increases in arterial oxygen content after NIV were also considerable in both groups (p < 0.05). Central venous pressure and systemic vascular resistance index values increased notably only after PSV (p < 0.05).
From these data, we deduce that APCV can be a better alternative to PSV for NIV in COPD patients with AHRF owing to its more beneficial physiological effects.
无创通气(NIV)在高碳酸血症型慢性阻塞性肺疾病(COPD)患者中的应用越来越广泛,但最合适的通气模式仍不明确。
本研究旨在探讨对于急性高碳酸血症性呼吸衰竭(AHRF)的COPD患者,辅助压力控制通气(APCV)是否可成为压力支持通气(PSV)用于NIV的更好替代方案。
在这项前瞻性随机研究中,我们评估了34例连续性AHRF的COPD患者接受无创APCV和PSV的早期效果。患者被随机分为两种模式中的一种,并在NIV 1小时前后比较呼吸和血流动力学值。
两组的基线值无差异。与基线相比,APCV组的动脉血二氧化碳分压和pH值有显著改善(p < 0.05)。两组的心输出量和心脏指数均下降(p < 0.05),但PSV组下降更显著(p < 0.0001)。两组在NIV后每搏量指数的下降和动脉血氧含量的增加也相当明显(p < 0.05)。仅在PSV后中心静脉压和全身血管阻力指数值显著升高(p < 0.05)。
从这些数据中,我们推断,对于AHRF的COPD患者,APCV因其更有益的生理效应,可成为PSV用于NIV的更好替代方案。